Business Context and Reporting Period
This Form 6-K filing by Wetour Robotics Limited covers the month of August 2026, specifically dated August 26, 2026. The report details the entry into a new sales agreement to facilitate an "at-the-market" offering of the company's ordinary shares.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the terms of a new securities offering arrangement.
Material Changes
The primary material change reported is the execution of a Sales Agreement with Rodman & Renshaw LLC. Under this agreement, the Company may issue and sell ordinary shares from time to time through an at-the-market offering. The Sales Agent will act as a sales agent and/or principal, utilizing commercially reasonable efforts to place shares on the Nasdaq Capital Market or other trading venues.
Guidance, Outlook, and Transaction Terms
- Commission Structure: The Sales Agent is entitled to a commission of up to 3.0% of the gross proceeds from sales where it acts as a sales agent.
- Expenses: The Company will reimburse the Sales Agent for reasonable, documented out-of-pocket expenses, including legal fees.
- Net Proceeds: Net proceeds will be calculated after deducting commissions, reimbursable expenses, and any applicable transaction fees.
- Registration: The offering is registered under the Company's shelf registration statement on Form F-3 (Registration No. 333-294373), supplemented by a prospectus dated August 26, 2026.
- Termination: Both parties retain the right to terminate the Sales Agreement by providing written notice as specified in the contract.
Investor Verification Checklist
- Verify the total number of shares authorized for sale under the shelf registration statement (Form F-3, No. 333-294373).
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific conditions precedent and termination clauses.
- Monitor future filings for actual share issuances and the corresponding gross proceeds generated under this agreement.
- Assess the impact of the 3.0% commission and expense reimbursements on the Company's future capital raising efficiency.